Argenx to buy peptide partner Unnatural Products in pursuit of oral immunology drugs
Argenx will pay $550 million in cash upfront and up to $595 million in milestones for the Santa Cruz, Calif., macrocyclic peptide company, in which it already owns a stake.

- Value
- $550M
- Type
- Acquisition
- Target
- Unnatural Products
- Buyer
- argenx
- Sector
- Biotech
- Announced
- Nov. 9, 2026
Argenx, a Netherlands-based antibody drug developer, is paying $550 million upfront for a different kind of molecule. The immunology drugmaker said Nov. 9 it will acquire Unnatural Products, known as UNP, a Santa Cruz, Calif., developer of macrocyclic peptides.
Argenx already owns part of UNP and will buy the remaining shares. On top of the upfront payment, which comes from cash on hand, UNP's holders could get as much as $595 million more if certain development and regulatory goals are met, putting the total potential price at about $1.15 billion. Both boards approved the deal, which should close before year-end.
Why it matters: Argenx said the platform could let it pursue pill-form or long-acting treatments for serious immune-mediated diseases. Macrocyclic peptides are bigger and more intricate than standard small-molecule drugs, which can help them grip hard-to-reach proteins, yet they can still be small enough to take as a pill, BioPharma Dive explained.
Leerink Partners analyst Thomas Smith wrote that drugmakers in immunology and beyond want to make oral, long-acting therapies that could be more convenient than conventional biologics, according to the outlet. He said the deal "represents potential for longer-term strategic value."
What UNP brings
UNP describes its platform as pairing parallel experimentation with machine learning to work through the hard medicinal chemistry of macrocyclic peptides. It is building a portfolio of macrocycles aimed at targets it calls high-value and traditionally difficult to drug. The announcement did not name UNP's programs or their stage of development.
UNP's approach has also attracted large drugmakers including Merck & Co. and Novartis, BioPharma Dive reported.
Karen Massey, argenx's chief executive, said UNP's capabilities are "highly complementary to our antibody engineering." She noted the two companies have worked together for more than two years.
After closing, UNP's leaders and staff will stay in Santa Cruz, which will become argenx's peptide discovery hub. UNP will keep leading discovery under a strategic framework the two companies agreed on, and argenx will take on clinical development and commercialization. Cameron Pye, UNP's chief executive and co-founder, said argenx offers the right setting to speed up the company's work.
Argenx's flagship product, Vyvgart, generated net product sales of $4.5 billion in the first nine months of the year, BioPharma Dive reported. Vyvgart targets generalized myasthenia gravis, an uncommon autoimmune disease that has drawn several developers, according to the outlet. One of them, UCB, won FDA approval in 2023 for Zilbrysq, a macrocyclic peptide for the disease.
The UNP deal follows argenx's purchase of Forte Biosciences, which BioPharma Dive described as potentially worth $2.2 billion. It also follows other biotech acquisitions this fall, including Merck KGaA's roughly $1.3 billion agreement for Silence Therapeutics in October.
Morgan Stanley is argenx's exclusive financial adviser and DLA Piper its legal adviser. Latham & Watkins is legal counsel to UNP.
What comes next
Closing is expected before year-end, subject to customary conditions. After that, the milestone schedule becomes the measure to watch: up to $595 million of the price depends on development and regulatory progress that the announcement did not tie to specific programs or dates.



